Effects of 5 ARBs on blood pressure, glucose and lipid metabolism, renal and heart function, and inflammation markers (Earnest)

Effects of 5 ARBs on blood pressure, glucose and lipid metabolism, renal and heart function, and inflammation markers (Earnest) - Earnest

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000442

Enrollment

300

Registered

2006-07-05

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Losartan group Start with once-daily dosing of losartan 25-50 mg, and increase up to 50-100 mg if effect of losartan on the clinical parameters is insufficient. Telmisartan group Start with once-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Blood pressure >= 140/90 >= 130/80 for patients with diabetes or chronic kidney diseases

Exclusion criteria

Exclusion criteria: Patients already receiving ARBs Pregnant women, or women suspected of being pregnant Hyperkalemia Bilateral renal artery stenosis Patients with history of hypersensitivity to the administered ARB Patients with severe liver disorder (losartan) Patients with severe defect in biliary drainage from liver or severe hepatic disorder (telmisartan)

Design outcomes

Primary

Measure	Time frame
1. Waist circumference 2. Blood pressure, Ambulatory blood pressure 3. FPG, IRI, HbA1c, (IRI, PG during OGTT) 4. Proteinuria, albuminuria, urinary creatinine, BUN 5. TC (or LDL-C), TG, HDL-C 6. BNP 7. hs-CRP, adiponectin 8. baPWV	—

Countries

Japan

Contacts

Public ContactKazuaki Uchino

Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine

uchinok@med.yokohama-cu.ac.jp045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026